ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Abstract

Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.

• Authors: Hee Kyung Ahn, Boram Han, Su Jin Lee, Taekyu Lim, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park
• Journal: Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 76 Issue 2 Pg. 253-4 (May 2012) ISSN: 1872-8332 [Electronic] Ireland
• PMID: 22385925 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Protein Kinase Inhibitors
• Pyrazoles
• Pyridines
• Crizotinib
• ALK protein, human
• Anaplastic Lymphoma Kinase
• Receptor Protein-Tyrosine Kinases
• Methotrexate

Topics

• Aged
• Anaplastic Lymphoma Kinase
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, enzymology, metabolism)
• Crizotinib
• Female
• Humans
• Lung Neoplasms (drug therapy, enzymology, metabolism)
• Male
• Meningeal Carcinomatosis (drug therapy, metabolism)
• Methotrexate (administration & dosage)
• Middle Aged
• Protein Kinase Inhibitors (administration & dosage)
• Pyrazoles (administration & dosage)
• Pyridines (administration & dosage)
• Receptor Protein-Tyrosine Kinases (antagonists & inhibitors, metabolism)